“The development of Muse, a result of our ongoing collaboration with OpenAI and Formation Bio, represents another proof point ...

From the company's own site, we can see this pharma brand has a diversified portfolio of therapies across multiple clinical ...

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

The third new business unit – emerging markets – bundles Sanofi's generic medicines and older products still in patent with the company's consumer healthcare products, emphasising that in ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

The emergence of regulatory concerns over the sale have hit Sanofi shares this week, and the company will be under pressure to communicate a clear plan when it reports third quarter earnings next ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Zucara Therapeutics Inc., ("Zucara" or the "Company") a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people ...

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings ... estimate of 4 billion euros in a poll posted on the company's website. Vaccines sales rose a currency-adjusted 25.5 ...